Celgene's most recent trend suggests a bullish bias. One trading opportunity on Celgene is a Bull Put Spread using a strike $130.00 short put and a strike $125.00 long put offers a potential 40.06% return on risk over the next 16 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $130.00 by expiration. The full premium credit of $1.43 would be kept by the premium seller. The risk of $3.57 would be incurred if the stock dropped below the $125.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Celgene is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Celgene is bullish.
The RSI indicator is at 41.35 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
Why bluebird bio Inc and Juno Therapeutics Inc Shot Higher Today
Mon, 28 Aug 2017 17:40:00 +0000
The biotechs' surge is related to a big move for fellow immuno-oncology drug developer Kite Pharma.
Juno Therapeutics: Celgene's Next Target?
Mon, 28 Aug 2017 15:09:00 +0000
As is typical following announcements of an acquisition, companies conducting research similar to Kite Pharma (KITE) have popped after Gilead Sciences' (GILD) announcement that it had agreed to the CAR-T …
See what the IHS Markit Score report has to say about Celgene Corp.
Mon, 28 Aug 2017 12:01:37 +0000
Celgene Corp NASDAQ/NGS:CELG
Why You Can Back Up the Truck and Load Up on This Biotech Stock
Sun, 27 Aug 2017 13:09:00 +0000
Celgene's bright prospects make the biotech stock a bargain right now that investors shouldn't pass up.
Consider This Before You Buy Biogen
Sun, 27 Aug 2017 12:01:00 +0000
New drugs that compete against Biogen's franchise of top-selling multiple sclerosis medicine pose a threat to Biogen's revenue.
Related Posts
Also on Market Tamer…
Follow Us on Facebook